{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/immunizations-travel/management/hepatitis-a/","result":{"pageContext":{"chapter":{"id":"422ff6d3-5810-5d3c-93b3-c5a67faaa0e1","slug":"hepatitis-a","fullItemName":"Scenario: Hepatitis A","depth":2,"htmlHeader":"<!-- begin field 633e0ef4-482a-491f-ba46-6c2074df4e32 --><h2>Scenario: Hepatitis A</h2><!-- end field 633e0ef4-482a-491f-ba46-6c2074df4e32 -->","summary":"Covers advice for people travelling to areas endemic with hepatitis A.","htmlStringContent":"<!-- begin item 01aaf742-a218-4539-b501-d8fe5e384b18 --><!-- begin field 9f6e12bd-1753-4d41-b9a6-acd900ab5240 --><p>From age 12 months onwards.</p><!-- end field 9f6e12bd-1753-4d41-b9a6-acd900ab5240 --><!-- end item 01aaf742-a218-4539-b501-d8fe5e384b18 -->","topic":{"id":"8f89ca7f-a4f5-5e7d-80c8-de5db64ca7f0","topicId":"16d61716-d647-48bc-827b-b2b115ecd0fb","topicName":"Immunizations - travel","slug":"immunizations-travel","lastRevised":"Last revised in January 2021","chapters":[{"id":"25b90177-7e96-59db-b325-abc5f51c8721","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"bc7c22b0-dd64-50ad-8110-1fff4c8d6736","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"50f55046-7ca2-567f-94df-9c58f13770a5","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"2221cdd9-5576-5b5b-ad29-eff077930653","slug":"changes","fullItemName":"Changes"},{"id":"c755b06c-072d-5e60-be73-155dd664c37d","slug":"update","fullItemName":"Update"}]},{"id":"f5871d9a-dff3-59ce-a611-88d2ec41f5ce","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"513a86a0-e305-5e59-bd0d-1fb74a6e8689","slug":"goals","fullItemName":"Goals"},{"id":"87ea4699-bd41-5aeb-aa62-eac1fb591c4d","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c8b054a0-ee87-5f9e-aa8f-c1fdf8442a29","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"a8eb4582-f05d-5af5-ae78-497260724f93","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"6f29b0b8-4b10-5e26-9ece-4cec050b1eb0","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"79cb1d1a-ebd1-58c6-9bc5-2bfd006c22c1","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"8d3187f5-2a99-5108-a7c9-dd601d729381","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"055aad08-f5af-5b2f-bda0-a35213a2a071","slug":"travel-vaccinations","fullItemName":"Travel vaccinations"},{"id":"c8d1352b-616b-5dff-9517-ea235b83e9d9","slug":"diseases-commonly-requiring-vaccination","fullItemName":"Diseases commonly requiring vaccination"},{"id":"041fa115-033d-5525-91ce-c43dbf593bd4","slug":"other-diseases-requiring-vaccination","fullItemName":"Other diseases requiring vaccination"},{"id":"1fe14ee1-a79f-565a-9380-ae3be597d7d5","slug":"where-these-diseases-are-prevalent","fullItemName":"Where these diseases are prevalent"},{"id":"68e09f74-2282-532f-ae34-064998823fc1","slug":"payment-for-travel-vaccinations","fullItemName":"Payment for travel vaccinations"}]},{"id":"0e45089d-2317-5ec5-8c73-f0709c003c48","fullItemName":"Management","slug":"management","subChapters":[{"id":"9c16c0cb-4e78-523d-914f-e884aea62565","slug":"initial-assessment-advice","fullItemName":"Scenario: Initial assessment and advice"},{"id":"f911dc04-ffd0-5a41-a3cb-b724797a7589","slug":"cholera","fullItemName":"Scenario: Cholera"},{"id":"422ff6d3-5810-5d3c-93b3-c5a67faaa0e1","slug":"hepatitis-a","fullItemName":"Scenario: Hepatitis A"},{"id":"01d49a70-70f4-547a-a551-ab524f99c944","slug":"hepatitis-b","fullItemName":"Scenario: Hepatitis B"},{"id":"5c77503c-2f59-5696-908b-125fe0e8e41c","slug":"japanese-encephalitis","fullItemName":"Scenario: Japanese encephalitis"},{"id":"8cb4ca86-fe31-5603-a75e-84413c2b5346","slug":"meningococcal-meningitis","fullItemName":"Scenario: Meningococcal meningitis"},{"id":"0e84be27-375b-55f5-9f51-d0e4cc422b58","slug":"poliomyelitis","fullItemName":"Scenario: Poliomyelitis"},{"id":"37a96f8b-4158-5e62-8e3d-6cedae506976","slug":"rabies","fullItemName":"Scenario: Rabies"},{"id":"8c237a0e-a760-55b2-b7b0-5383b7653be3","slug":"tetanus","fullItemName":"Scenario: Tetanus"},{"id":"85c90e1f-26f4-503b-b0b0-7c5a38930086","slug":"tick-borne-encephalitis","fullItemName":"Scenario: Tick-borne encephalitis"},{"id":"4e817d26-15f3-5ff7-a672-11caa36ffb68","slug":"typhoid-fever","fullItemName":"Scenario: Typhoid fever"},{"id":"5ec20606-2af2-556b-98a6-d8673a21a09d","slug":"yellow-fever","fullItemName":"Scenario: Yellow fever"},{"id":"e0a021ac-7c76-551a-97af-25341142d54f","slug":"hajj-umrah-pilgrims","fullItemName":"Scenario: Hajj and Umrah pilgrims"},{"id":"087d9fbb-1ec6-5f08-8e76-5df3a4a0b863","slug":"rapid-vaccination-courses-vaccination-at-short-notice","fullItemName":"Scenario: Rapid vaccination courses and vaccination at short notice"}]},{"id":"79dee816-dbdb-5426-8db3-2f095eedbff3","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"f1e9d43f-6815-516a-8511-3fd34a06525d","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a69fb594-d4b4-56e6-b46a-6283ead93e30","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"52eea726-d50b-5e4f-a22c-764c1961119d","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b2033c1b-25a2-5a58-b99e-00baf9b02a96","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"6df4842b-8812-534e-975d-52d29f3a8ee4","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"81e42472-4b49-5390-8179-0d131f547700","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"86482706-09b2-5113-bd4e-261c392f6483","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"0e45089d-2317-5ec5-8c73-f0709c003c48","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"f3204e33-49bf-5ffb-86b7-e987f33836fc","slug":"indications-for-vaccine","fullItemName":"Indications for vaccine","depth":3,"htmlHeader":"<!-- begin field 865c36b4-c274-4230-8252-764571abebd1 --><h3>Indications for vaccine</h3><!-- end field 865c36b4-c274-4230-8252-764571abebd1 -->","summary":null,"htmlStringContent":"<!-- begin item 76ce22f2-4db2-4e53-84e3-75ac0b6103ed --><!-- begin field 62960672-04e3-462b-8bff-315e02e72372 --><ul><li><strong>Vaccination against hepatitis A is recommended for:</strong><ul><li>Anyone aged 1 year and over travelling to areas where hepatitis A vaccination is recommended (such as the Indian subcontinent), particularly for prolonged periods, and/or if sanitation and food hygiene is likely to be poor. For up-to-date information about the travel areas for which hepatitis A vaccination is recommended, please see the <a href=\"https://travelhealthpro.org.uk/countries\" data-hyperlink-id=\"f1e45640-fe68-4feb-852a-accc00c0dac4\">Country Information</a> section of the <a href=\"https://travelhealthpro.org.uk/\" data-hyperlink-id=\"2bc619f0-c97a-44d9-b349-accc00c0dac4\">TravelHealthPro</a> website.<ul><li>Hepatitis A vaccination is <em>not</em> recommended for children under the age of 1 year.</li></ul></li><li>Individuals going to live in, or likely to be posted for long periods to, hepatitis A virus-endemic <a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-travel/background-information/where-these-diseases-are-prevalent/\">countries</a>.</li></ul></li><li><strong>If rapid protection against hepatitis A is required, for example following exposure or during outbreaks, then a single dose of monovalent vaccine is generally preferred</strong> as this may provide protection more quickly than the two courses of combined vaccine.</li><li><strong>Give combined vaccines if:</strong><ul><li>Protection against both hepatitis A and hepatitis B infections is required, <em>or</em></li><li>Protection against hepatitis A and typhoid fever is required (frequently endemic in the same areas).</li></ul></li><li><strong>Immunization is <em>not</em> considered necessary for individuals travelling to or going to reside in Northern or Western Europe</strong> (including Spain, Portugal, and Italy), or North America, Australia, or New Zealand.<ul><li>For up to date country-by-country advice see the <a href=\"http://travelhealthpro.org.uk/\" data-hyperlink-id=\"fe848da6-5f0c-4bc7-840d-a931009e8305\">TravelHealthPro</a> website.</li><li>Other specific indications for hepatitis A vaccination are described in the Department of Health publication <em>Immunisation against infectious disease </em>(<a href=\"https://www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-book\" data-hyperlink-id=\"26e5c4e6-c962-4879-8d39-a931009e8387\">The Green Book</a>).</li></ul></li></ul><!-- end field 62960672-04e3-462b-8bff-315e02e72372 --><!-- end item 76ce22f2-4db2-4e53-84e3-75ac0b6103ed -->","subChapters":[{"id":"d96f4984-0a1b-5434-b5a7-b282da245bc6","slug":"basis-for-recommendation-0e4","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 0ede73a5-86e0-456e-aaba-fbe42a4107e5 --><h4>Basis for recommendation</h4><!-- end field 0ede73a5-86e0-456e-aaba-fbe42a4107e5 -->","summary":null,"htmlStringContent":"<!-- begin item 0e4e66e0-f080-4e01-9fc9-849c6703ffb4 --><!-- begin field 0951d04e-f437-4e3c-8c70-5290cfbf1cf6 --><p>The recommendations on indications for hepatitis A vaccination are based on expert opinion in the Department of Health publication <em>Immunisation against infectious disease (The Green Book) Chapter 17: Hepatitis A</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">PHE, 2013a</a>].</p><h5>Children under 1 year of age</h5><ul><li>Hepatitis A vaccination is <em>not</em> recommended for children under the age of 1 year as the risk of disease in this age group is considered to be low, and the vaccines are not licensed for use in this age group.</li></ul><!-- end field 0951d04e-f437-4e3c-8c70-5290cfbf1cf6 --><!-- end item 0e4e66e0-f080-4e01-9fc9-849c6703ffb4 -->","subChapters":[]}]},{"id":"6a38f20a-2a29-5669-bcb5-201013427e41","slug":"available-vaccines-vaccination-schedules","fullItemName":"Available vaccines and vaccination schedules","depth":3,"htmlHeader":"<!-- begin field eb0bc00c-9584-4414-9466-27b0f22d7791 --><h3>Available vaccines and vaccination schedules</h3><!-- end field eb0bc00c-9584-4414-9466-27b0f22d7791 -->","summary":null,"htmlStringContent":"<!-- begin item 6cce18d8-3872-460b-ae2c-f9e872a0090d --><!-- begin field 158c890c-b894-4531-acb7-50f29dc5497a --><ul><li><strong>There are several hepatitis A vaccines licensed for use in the UK, all of which are inactivated and prepared from different strains of the hepatitis A virus. These are:</strong><ul><li>Avaxim<sup>®</sup>.</li><li>Epaxal<sup>®</sup>.</li><li>Havrix Monodose<sup>®</sup>.</li><li>Havrix Junior Monodose<sup>®</sup>.</li><li>Vaqta<sup>®</sup>.</li><li>Vaqta<sup>® </sup>Paediatric.</li></ul></li><li>The primary vaccination schedule for monovalent hepatitis A vaccines is a single dose, ideally given at least 2 weeks before travelling. However, it can also be given up to the day of departure. Protection from a single dose lasts for 1 year.</li><li>Reinforcing doses can be given to people at continued risk. For details, please see Table 3.</li><li>Combined hepatitis A and B (Ambirix<sup>®</sup>, Twinrix Adult<sup>®</sup>,<sup> </sup>Twinrix Paediatric<sup>®</sup>) and hepatitis A and typhoid (Hepatyrix<sup>®</sup>, ViATIM<sup>®</sup>) vaccines are also available.</li><li>Be aware that due to a global shortage of monovalent hepatitis A vaccine, Public Health England has issued temporary guidance on hepatitis A vaccination in adults to promote dose sparing and preservation of monovalent hepatitis A vaccine stock for those most likely to benefit. In order to select the most appropriate hepatitis A vaccine for adult travellers where supply issues have been noted, prescibers are encouraged to consult the PHE document <a href=\"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/626228/Hepatitis_A_vaccination_recommendations.pdf\" data-hyperlink-id=\"f1b8a232-3947-44f5-8cda-accd00ff0461\">Hepatitis A vaccination in adults: temporary recommendations</a>.</li></ul><p><strong>Table 3. </strong>Schedule for monovalent hepatitis A vaccination. For vaccination schedules for combined hepatitis A vaccines, please see the chapter on hepatitis A immunization in <a href=\"https://www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-book\" data-hyperlink-id=\"6ffb25ad-44b8-4d59-89bd-a93100a04af3\">The Green Book</a>.</p><table data-table-id=\"78cc6486-0ba4-473f-a1f8-acce014c4517\"><thead><tr><th><p>Vaccine</p></th><th><p>Full schedule</p></th><th><p>Length of protection</p></th><th><p>Age</p></th></tr></thead><tbody><tr><td>Avaxim<sup>®</sup></td><td>2 doses, given 6–12 months apart.</td><td>25 years after second dose.</td><td>Adults from 16 years.</td></tr><tr><td>Havrix Monodose<sup>®</sup></td><td>2 doses, given 6–12 months apart.</td><td>25 years after second dose.</td><td>Adults from 16 years.</td></tr><tr><td>Havrix Junior Monodose<sup>®</sup></td><td>2 doses, given 6–12 months apart.</td><td>25 years after second dose.</td><td>Children from 1 year to 15 years.</td></tr><tr><td>Vaqta<sup>®</sup> </td><td>2 doses, given 6–18 months apart.</td><td>25 years after second dose.</td><td>Adults from 18 years.</td></tr><tr><td>Vaqta<sup>®</sup> Paediatric</td><td>2 doses, given 6–18 months apart.</td><td>25 years after second dose.</td><td>Children from 1 year to 17 years.</td></tr></tbody></table><ul><li>If the second dose has been missed there is no need to restart immunization. Give the second dose as soon as possible after the missed date.</li><li>If a combined hepatitis A and typhoid vaccine has been used to start immunization, give a booster dose of single hepatitis A vaccine 6–12 months later.</li><li>If a combined hepatitis A and B vaccine has been given in an accelerated schedule, a booster dose is required at 1 year.</li></ul><!-- end field 158c890c-b894-4531-acb7-50f29dc5497a --><!-- end item 6cce18d8-3872-460b-ae2c-f9e872a0090d -->","subChapters":[{"id":"ed67ae51-774a-57ae-bf64-0a66a4b4921c","slug":"basis-for-recommendation-eee","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field c61bb2f8-7222-4542-a7d6-d9b990843194 --><h4>Basis for recommendation</h4><!-- end field c61bb2f8-7222-4542-a7d6-d9b990843194 -->","summary":null,"htmlStringContent":"<!-- begin item eeed1545-c910-4545-a248-d00d9dfe42b6 --><!-- begin field 50afcfd7-4b05-4a12-8886-543a2b0af2cc --><p>The information on available types of hepatitis A vaccine and vaccination schedules is based on expert opinion in the Department of Health publication <em>Immunisation against infectious disease (The Green Book) Chapter 17: Hepatitis A</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">PHE, 2013a</a>] and on the manufacturer's Summary of Product Characteristics for VAQTA<sup>® </sup>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">ABPI, 2020a</a>].</p><h5>Dose-sparing guidance from Public Health England (PHE)</h5><ul><li>In order to preserve stocks of monovalent hepatitis A vaccines, PHE has issued temporary guidance suggesting the first-line use of combined Hepatitis A vaccines and/or paediatric preparations of vaccines in some cohorts of travellers. Due to the temporary nature of these recommendations, CKS suggests that where vaccine supply issues have been noted, prescribers directly consult the PHE document <em>Hepatitis A vaccination in adults: temporary recommendations</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">PHE, 2017b</a>] in order to determine the most appropriate vaccine.</li></ul><!-- end field 50afcfd7-4b05-4a12-8886-543a2b0af2cc --><!-- end item eeed1545-c910-4545-a248-d00d9dfe42b6 -->","subChapters":[]}]},{"id":"71f321f2-5316-5d25-86aa-c163276cc3b6","slug":"contraindications-to-vaccine","fullItemName":"Contraindications to vaccine","depth":3,"htmlHeader":"<!-- begin field f7d9ad2e-d673-432a-b470-a041b36c05c1 --><h3>Contraindications to vaccine</h3><!-- end field f7d9ad2e-d673-432a-b470-a041b36c05c1 -->","summary":null,"htmlStringContent":"<!-- begin item 14e54bc2-5ad4-4b3f-987d-b3bf0b4f48b1 --><!-- begin field 74fb313d-5709-4890-bce2-d8740812bb7a --><ul><li><strong>Do not give hepatitis A vaccine if the person has:</strong><ul><li>Had a confirmed anaphylactic reaction to a previous dose of hepatitis A vaccine.</li><li>Had a confirmed anaphylactic reaction to any component of hepatitis A vaccine.<ul><li>Epaxal<sup>® </sup>should not be given to those who have had a confirmed anaphylactic hypersensitivity to egg products as it is prepared on hen's eggs.</li></ul></li></ul></li><li><strong>Postpone hepatitis A vaccination if the person has a current severe febrile illness.</strong><ul><li>Minor illness without fever or systemic upset is <em>not</em> a valid reason to postpone immunization.</li></ul></li><li><strong>Hepatitis A vaccines may be given to pregnant women when clinically indicated.</strong> There is no evidence of risk from vaccinating pregnant women or those who are breastfeeding with inactivated virus, bacterial vaccines, or toxoids.</li></ul><!-- end field 74fb313d-5709-4890-bce2-d8740812bb7a --><!-- end item 14e54bc2-5ad4-4b3f-987d-b3bf0b4f48b1 -->","subChapters":[{"id":"ffcaf51a-5c82-5e5d-9e49-f0c02647f274","slug":"basis-for-recommendation-1b4","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field ab50b48e-7a4e-44c1-9709-38c7a69d3438 --><h4>Basis for recommendation</h4><!-- end field ab50b48e-7a4e-44c1-9709-38c7a69d3438 -->","summary":null,"htmlStringContent":"<!-- begin item 1b4107c2-4f6c-46ac-8d22-bff4e5cac0e2 --><!-- begin field d6534c35-01d0-4afc-8246-fef30fdf3b91 --><p>The information on contraindications to hepatitis A vaccination is based on expert opinion in the Department of Health publication <em>Immunisation against infectious disease (The Green Book) Chapter 17: Hepatitis A</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">PHE, 2013a</a>] and <em>Chapter 6: Contraindications and special considerations</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">PHE, 2017a</a>].</p><!-- end field d6534c35-01d0-4afc-8246-fef30fdf3b91 --><!-- end item 1b4107c2-4f6c-46ac-8d22-bff4e5cac0e2 -->","subChapters":[]}]},{"id":"b51be3e3-dff3-5f64-bb89-c28a0e9e3e2b","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field cb5afc3f-cfb0-4e2a-829e-722830df767a --><h3>Adverse effects</h3><!-- end field cb5afc3f-cfb0-4e2a-829e-722830df767a -->","summary":null,"htmlStringContent":"<!-- begin item 1f9a5ecb-482a-4353-91c0-9f957602ae30 --><!-- begin field a7203e20-c862-47f1-815b-2bbca8cd75f2 --><ul><li>Adverse reactions to hepatitis A vaccines are usually mild and confined to the first few days after immunization.</li><li>The most common reactions are mild, transient soreness, erythema, and induration at the injection site.</li><li>A small, painless nodule may form at the injection site; this usually disappears and is of no consequence.</li><li>General symptoms such as fever, malaise, fatigue, headache, nausea, and loss of appetite are also reported less frequently.</li></ul><!-- end field a7203e20-c862-47f1-815b-2bbca8cd75f2 --><!-- end item 1f9a5ecb-482a-4353-91c0-9f957602ae30 -->","subChapters":[{"id":"2d2bee4e-b5a1-51f0-bf5c-645634b1e927","slug":"basis-for-recommendation-4b2","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 16c40319-3c0b-438f-a681-550f4b44d775 --><h4>Basis for recommendation</h4><!-- end field 16c40319-3c0b-438f-a681-550f4b44d775 -->","summary":null,"htmlStringContent":"<!-- begin item 4b2b8666-617d-45bf-ac92-bbfee135cc7f --><!-- begin field 1e7d42b4-4d52-4008-aa47-719350d4b903 --><p>The information on adverse reactions to hepatitis A vaccination is based on expert opinion in the Department of Health publication <em>Immunisation against infectious disease (The Green Book) Chapter 17: Hepatitis A</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">PHE, 2013a</a>].</p><!-- end field 1e7d42b4-4d52-4008-aa47-719350d4b903 --><!-- end item 4b2b8666-617d-45bf-ac92-bbfee135cc7f -->","subChapters":[]}]},{"id":"629060ba-b146-5756-b2bf-3caa0a049c14","slug":"how-to-administer-hepatitis-a-vaccine","fullItemName":"How to administer hepatitis A vaccine","depth":3,"htmlHeader":"<!-- begin field a8deef43-3be9-42c6-a421-9aed91079e36 --><h3>How to administer hepatitis A vaccine</h3><!-- end field a8deef43-3be9-42c6-a421-9aed91079e36 -->","summary":null,"htmlStringContent":"<!-- begin item 4a331b7f-e6da-48c8-970e-d3e5ee53d69a --><!-- begin field b744a2da-cd51-4df4-9017-cd22f470fff5 --><ul><li><strong>Obtain written or verbal consent at the time of vaccination for people aged over 16 years.</strong><strong> For younger people it is usual to get consent from a person with parental responsibility.</strong><ul><li>Adults over 18 years of age are presumed to be competent to consent to treatment provided they can comprehend and retain the information they are given, and they can consider the facts and make an informed decision.</li></ul></li><li><strong>Ensure that:</strong> <ul><li>There are no <a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-travel/management/hepatitis-a/#contraindications-to-vaccine\">contraindications</a> to the vaccine.</li><li>The person, parent, or carer has been fully informed about the vaccine and the vaccination procedure.</li><li>Possible <a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-travel/management/hepatitis-a/#adverse-effects\">adverse reactions</a> have been discussed and the person, parent, or carer is aware of how to manage them. </li><li>The vaccine is correct, has been stored appropriately, and has not expired. </li></ul><ul><li>The vaccination site has been washed with soap and water if it is visibly dirty. </li></ul></li><li><strong>Hepatitis A vaccine is usually given by intramuscular (IM) injection,</strong> into the upper arm in children over 1 year of age and adults. However, if the person has a bleeding disorder, the vaccine should be given by deep subcutaneous (SC) injection to reduce the risk of bleeding. </li><li><strong>Hepatitis A vaccine can be given at the same time as other vaccines.</strong> If an additional vaccine is required on the same day, use separate limbs if possible, or inject at sites at least 2.5 cm apart. </li><li><strong>Record the date of administration, vaccine and product name, batch number, expiry date, dose administered, and site of administration for each vaccine.</strong> </li><li><strong>Observe the person after vaccination to detect immediate adverse reactions.</strong> Ensure any bleeding has stopped and check for any symptoms of anaphylaxis before they leave.<ul><li>Anaphylaxis is extremely rare, and usually becomes apparent within minutes. By the time the site has been checked for bleeding and documentation has been completed, most reactions will have become apparent. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a>.</li></ul></li></ul><!-- end field b744a2da-cd51-4df4-9017-cd22f470fff5 --><!-- end item 4a331b7f-e6da-48c8-970e-d3e5ee53d69a -->","subChapters":[{"id":"df7744d1-49c8-5d46-bdac-560df11bba61","slug":"basis-for-recommendation-582","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 21026606-047e-4d3a-935f-aa496f43f81f --><h4>Basis for recommendation</h4><!-- end field 21026606-047e-4d3a-935f-aa496f43f81f -->","summary":null,"htmlStringContent":"<!-- begin item 58214834-10e2-4b55-a736-98ecded63dec --><!-- begin field 77e48585-bd3b-4db6-9711-08eb833d76f0 --><p>These recommendations are based on expert opinion in the Department of Health Publication <em>Immunisation against infectious disease</em> <em>(The Green Book)</em> in <em>Chapter 17: Hepatitis A</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">PHE, 2013a</a>], <em>Chapter 2: Consent</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">PHE, 2013e</a>], <em>Chapter 4: Immunisation procedures </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">PHE, 2013f</a>], and <em>Chapter 8: Vaccine safety and adverse effects </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">PHE, 2013g</a>], and are also pragmatic, based on what CKS considers to be good clinical practice.</p><h5>Obtaining consent</h5><ul><li>Consent for immunizations does not legally have to be in writing, but must be given voluntarily by a fully informed person who is able to make and communicate their decision. For children not competent to give or withhold consent, a person with parental responsibility can provide this [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">PHE, 2013e</a>].</li></ul><h5>Site of administration</h5><div><ul><li>In people over the age of 1 year, vaccines are routinely given into the deltoid muscle as it is convenient, providing easy access, and it reduces the risk of localized reactions, which are common when vaccines are given subcutaneously.</li><li>The gluteal muscle should be avoided. The needle may not penetrate through adipose tissue into the muscle, and this may cause a poor immunological response to the vaccine. In addition, there is a risk of damage to underlying structures such as the sciatic nerve [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">PHE, 2013f</a>].</li></ul></div><!-- end field 77e48585-bd3b-4db6-9711-08eb833d76f0 --><!-- end item 58214834-10e2-4b55-a736-98ecded63dec -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}